CXCR4及NDRG1蛋白在前列腺癌中的表达及其与侵袭转移的相关性分析

doi:10.3969/j.issn.1006-7795.2016.03.014

首都医科大学学报 ›› 2016, Vol. 37 ›› Issue (3): 327-330.doi: 10.3969/j.issn.1006-7795.2016.03.014

• 前列腺癌发病机制与临床治疗研究 • 上一篇下一篇

CXCR4及NDRG1蛋白在前列腺癌中的表达及其与侵袭转移的相关性分析

平浩, 牛亦农, 杨飞亚, 王明帅, 邢念增

首都医科大学附属北京朝阳医院泌尿外科, 北京 100020

收稿日期:2016-04-06 出版日期:2016-06-21 发布日期:2016-06-13
通讯作者: 平浩 E-mail:pinghaocy@163.com
基金资助:
首都医科大学基础临床科研合作基金(16JL60)。

Expression of CXCR4 and NDRG1 and its association with invasion and metastasis in prostate cancer

Ping Hao, Niu Yinong, Yang Feiya, Wang Mingshuai, Xing Nianzeng

Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

Received:2016-04-06 Online:2016-06-21 Published:2016-06-13
Supported by:
This study was supported by Capital Medical University Foundation-Clinical Research Cooperation Fund(16JL60).

摘要/Abstract

摘要： 目的探讨趋化因子受体4(chemokine receptor 4, CXCR4)及N-myc下游调节基因1(N-myc downstream regulated gene 1, NDRG1)在前列腺癌组织及细胞系中的表达情况,明确其与前列腺癌恶性程度及转移的关系。方法应用免疫组织化学方法检测CXCR4蛋白在前列腺癌(46例)、良性前列腺增生(15例)及正常前列腺组织(10例)中的表达,分析其与前列腺癌病理分级及转移的关系。免疫印迹(Western blotting)法检测不同前列腺癌细胞系中CXCR4及磷酸化NDRG1(pNDRG1)表达差异。结果免疫组织化学检测发现CXCR4蛋白在前列腺癌组织(30例)中过度表达,表达率为65.2%,其表达水平与前列腺癌病理分级及Gleason评分无显著相关性(P=0.081),而CXCR4蛋白表达与肿瘤转移密切相关,前列腺癌转移患者表达率明显高于无转移患者,差异有统计学意义(P=0.002)。Western blotting法检测在正常前列腺上皮细胞和不同前列腺癌细胞系中CXCR4及NDRG1蛋白表达不同,高转移潜能的去势抵抗前列腺癌细胞(PC3和DU145)中CXCR4表达较高,而作为转移抑制因子的pNDRG1表达则明显降低。结论趋化因子受体CXCR4及转移抑制因子NDRG1可能参与调控前列腺癌的进展和转移,对前列腺癌的临床诊断和治疗有重要价值。

关键词: 前列腺癌, 趋化因子受体4, N-myc下游调节基因1, 转移

Abstract: Objective To investigate the expression and clinical significance of CXCR4 and N-myc downstream regulated gene 1 (NDRG1) in prostate cancer (PCa), and explore the relation between the protein expression and metastasis in PCa. Methods The expression of CXCR4 was detected by immunohistochemistry in 46 cases of PCa, 15 cases of benign prostatic hyperplasia (BPH) and 10 cases of normal prostate tissues (NP). The relation between the expression and clinicopathological changes was analyzed statistically. CXCR4 and phosphorylated NDRG1 (pNDRG1) were examined by Western blotting in prostate cancer cells. Results The expression level of CXCR4 in PCa was significantly higher than those in BPH and NP. The over-expression rate of CXCR4 in PCa was 65.2%. The expression of CXCR4 protein was not significantly associated with pathological grade and Gleason score (P=0.081). However, the increased expression of CXCR4 protein was significantly associated with the presence of metastasis of PCa (P=0.002). By Western blotting analysis, the expression of CXCR4 protein was stronger in PC3 and DU145 than in PrEC and LNCap cell lines. However, the expression of pNDRG1 decreased in the prostate cancer cells with high metastasis potential. Conclusion The expressions of CXCR4 and pNDRG1 are closely related to metastasis of PCa. CXCR4 and pNDRG1 have significant clinical implications for diagnosis and treatment of PCa.

Key words: prostate cancer, chemokine receptor 4 (CXCR4), N-myc downstream regulated gene 1 (NDRG1), metastasis

中图分类号:

R737.25

平浩, 牛亦农, 杨飞亚, 王明帅, 邢念增. CXCR4及NDRG1蛋白在前列腺癌中的表达及其与侵袭转移的相关性分析[J]. 首都医科大学学报, 2016, 37(3): 327-330.

Ping Hao, Niu Yinong, Yang Feiya, Wang Mingshuai, Xing Nianzeng. Expression of CXCR4 and NDRG1 and its association with invasion and metastasis in prostate cancer[J]. Journal of Capital Medical University, 2016, 37(3): 327-330.

参考文献

[1] Burger J A, Kipps T J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment[J]. Blood, 2006, 107(5): 1761-1767.
[2] Sun J, Zhang D, Bae D H, et al. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors[J]. Carcinogenesis, 2013, 34(9):1943-1954.
[3] Jin R, Liu W, Menezes S, et al. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of b-catenin through mechanisms involving FRAT1 and PAK4[J]. J Cell Sci, 2014, 127(Pt14): 3116-3030.
[4] 江明友,万明发,冯亮,等. Oct4基因在前列腺癌中的表达及意义[J]. 中华老年医学杂志,2013,32(6):640-642.
[5] Raman D, Baugher P J, Thu Y M, et al. Role of chemokines in tumor growth[J]. Cancer Lett, 2007, 256(2):137-165.
[6] Sun X Q, Cheng G C, Hao M G, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression[J]. Cancer Metastasis Rev, 2010, 29(4):709-722.
[7] Yang D L, Xin M M, Wang J S, et al. Chemokine receptor CXCR4 and its ligand CXCL12 expressions and clinical significance in bladder cancer[J]. Genet Mol Res, 2015, 14(4):17699-17707.
[8] Bae D H, Jansson P J, Huang M L, et al. The role of NDRG1 in the pathology and potential treatment of human cancer[J]. J Clin Pathol, 2013, 66(11): 911-917.
[9] Song Y, Oda Y, Hori M, et al. N-myc downstream gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin[J]. Hum Pathol, 2010, 41(2): 214-222.
[10] Lee J Y, Kang D H, Chung D Y, et al. Meta-analysis of the relationship between CXCR4 expression and metastasis in prostate cancer[J]. World J Mens Health, 2014, 32(3): 167-175.
[11] Chen Q, Zhong T. The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review[J]. Drug Des Devel Ther, 2015, 9: 5115-5122.
[12] Wong D, Kandagatla P, Korz W, et al. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis[J]. BMC Urol, 2014, 14:12.
[13] Liu R L, Li J, Teng Z G, et al. Overexpressed MicroRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc down stream regulated gene 1(NDRG1)[J]. PLoS One, 2013, 8(7): e68982.
[14] 李小攀,杨琛,孙乔,等. 2002 2013年上海市浦东新区居民前列腺癌发病死亡趋势分析[J]. 中华肿瘤防治杂志,2015,22(6):412-415.
[15] 曹希亮,高江平. 晚期前列腺癌药物治疗研究进展[J]. 解放军医药杂志,2013,25(2):59-63.
[16] 罗勇. 局限性前列腺癌根治术与非手术治疗的对比研究[J]. 临床误诊误治,2013,26(1):107.
[17] 欧阳容兰,张栋梁,李小毅,等. 趋化因子受体CCR7的免疫学功能研究进展[J]. 解放军医药杂志,2015,27(4):108-112.

CXCR4及NDRG1蛋白在前列腺癌中的表达及其与侵袭转移的相关性分析

Expression of CXCR4 and NDRG1 and its association with invasion and metastasis in prostate cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	罗诗雨, 李眉, 罗莎, 王爽, 张娟, 李萌, 南潇, 鲜军舫. ¹⁸F-FDG PET/CT在脉络膜黑色素瘤与脉络膜转移癌鉴别诊断中的应用价值[J]. 首都医科大学学报, 2022, 43(6): 867-872.
[2]	刘群, 李丽娜, 刘健, 苗劲蔚. 卵巢癌SOX4介导TGF-β1诱导的上皮间质转化对侵袭转移能力的影响[J]. 首都医科大学学报, 2022, 43(3): 336-342.
[3]	蒋铭心, 苏瑶, 熊天宇, 叶小波, 靳松, 邢念增, 金木兰, 杨敏福, 牛亦农. 减瘤性根治性前列腺切除术对骨转移前列腺癌患者的临床疗效分析[J]. 首都医科大学学报, 2021, 42(6): 967-972.
[4]	王明帅, 熊天宇, 蒋铭心, 钱小松, 王思豪, 崔韵, 牛亦农. 改良前列腺尖部分离技术保留尿道周围结构对前列腺癌根治术后即刻尿控的影响[J]. 首都医科大学学报, 2021, 42(6): 973-977.
[5]	叶小波, 熊天宇, 崔韵, 王明帅, 杨辉, 安卓玲, 牛亦农. 醋酸阿比特龙联合强的松治疗去势抵抗型前列腺癌的疗效分析[J]. 首都医科大学学报, 2021, 42(6): 978-985.
[6]	王亚军, 康骅, 赵菁, 海涛, 张小丽, 蔡伟. 甲状腺微小乳头状癌中央区淋巴结转移影响因素的聚类分析研究[J]. 首都医科大学学报, 2021, 42(6): 1053-1059.
[7]	樊笑琪, 刘志斌, 王明帅, 瓦斯里江·瓦哈甫, 宋黎明, 邢念增, 牛亦农. 腹腔镜单纯尿道前壁加强法与尿道前后壁加强法(Sandwich法)改善前列腺癌根治术后早期尿控的对比分析[J]. 首都医科大学学报, 2020, 41(4): 542-546.
[8]	白志杰, 王新胜, 马洪顺, 李波. mpMRI与超声融合导航技术在前列腺靶向穿刺的临床研究[J]. 首都医科大学学报, 2020, 41(4): 631-635.
[9]	王明, 卜祥婷, 栾格, 王阳, 王成硕, 张罗. MALAT1在慢性鼻窦炎伴鼻息肉中的表达及对糖皮质激素治疗的反应性[J]. 首都医科大学学报, 2020, 41(2): 183-188.
[10]	王爱婷, 鄢丹, 齐宪荣. 包载多西他赛的聚合物胶束抑制小鼠乳腺癌转移作用研究[J]. 首都医科大学学报, 2020, 41(2): 225-230.
[11]	谢英伟, 金仕鹏, 李爽, 王永辉, 王伟, 平浩, 刘跃新. TMPRSS2-ERG融合基因与转移性去势抵抗性前列腺癌化学药物治疗后生存率的关系[J]. 首都医科大学学报, 2020, 41(1): 103-107.
[12]	姜波, 罗渝昆, 张艳, 田晓琦, 张颖, 谢芳, 宋青, 唐杰. 甲状腺乳头状癌的常规超声及超声造影特征与淋巴结转移的相关性[J]. 首都医科大学学报, 2019, 40(6): 818-823.
[13]	平浩, 马林祥, 王明帅, 龙军, 牛亦农, 刘跃新, 邢念增. 单羧酸转运蛋白4(MCT4)在前列腺癌中的表达及调控研究[J]. 首都医科大学学报, 2019, 40(1): 59-64.
[14]	王蔚, 苏嘉明, 袁东波, 张伟, 陈卫红, 孙兆林, 朱建国. 微管相关蛋白1A在前列腺癌中的表达与其临床特征的关系[J]. 首都医科大学学报, 2019, 40(1): 65-71.
[15]	谢英伟, 金世鹏, 闫伟, 王伟, 平浩, 刘跃新. TMPRSS2-ERG融合基因在淋巴结转移前列腺癌中的阳性率及与生存的关系[J]. 首都医科大学学报, 2019, 40(1): 72-77.